Navigation Links
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Date:3/2/2013

edict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timi
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
2. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
5. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
8. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
9. Sanofi Pasteur to add 2D barcode to six more vaccines
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Up Call as Lighthouse International and EHE International unveil a ... of New Yorkers will see a new warning sign in ... their vision. The sign, located at 10 Rockefeller Plaza and ... a l03-year-old leader in vision healthcare. It will be on ...
... Over 80 percent of Americans suffer from ... their skin, but their self esteem as well. Many reach ... in cosmetic products in the European Union and the desire ... are taking a hard look at their acne treatments and ...
... session in Orlando, FL will feature strategies and tools that increase ... ... Orlando, FL (Vocus) January 8, 2009 -- Facing unprecedented marketplace disruption ... consumer autonomy in health insurance selection - the retention of individual ...
... NEW ROCHELLE, N.Y., Jan. 8 Natural gas, believed to ... airborne particulate matter when burned in home appliances such as ... the December 2008 issue (Volume 25, Number 10) of ... Mary Ann Liebert, Inc. The paper ...
... and the University of Barcelona have shown that treatment ... pomace, results in a significant inhibition of cell proliferation ... is a novel natural compound and it is able ... colon-cancer cells via the intrinsic mitochondrial pathway. Scientifics suggest ...
... safety advocates to launch congressional campaign to prod all ... 40,000 deaths and $230 billion in economic losses.***Free Webcast ... Conference***WASHINGTON, Jan. 8 The following was issued by ... As state legislatures across the nation gear up for ...
Cached Medicine News:Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 2Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 3Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 2Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 3Health News:World Health Care Congress and Connextions Health Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 4Health News:Particulate Emission from Natural Gas Burning Home Appliances Is Assessed in Environmental Engineering Science Journal 2Health News:Each State to Receive Report Card Grading Their Progress in Passing Model Traffic Safety Laws 2
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... delicate urethral tissues. The gentle, ... provide nearly friction-free movement, without ... to maintain sterility. You simply ... own sterile water, avoiding contamination ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: